Attovia Q2 2026 net loss $20.7M; ATTO-1310 proof-of-concept; IPO funds runway to 2030

Attovia Therapeutics, Inc.

Q2 2026 net loss $20.7M vs $14.4M year ago; R&D $18.9M vs $13.6M; collaboration revenue $0.5M.
Cash $115.1M at 6/30/26; plus $305.4M net IPO proceeds (Aug '26) extends runway into 2030.
ATTO-1310 Phase 1b shows rapid itch relief in chronic pruritus and high-itch AD; full data Q4 2026.
Phase 2 studies in CPUO and high-itch AD planned 1H 2027; Phase 1 for ATTO-2306/1091 also 1H 2027.
IPO gross proceeds $332.4M; board strengthened with John W. Smither appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.